Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2261
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study ; volume:21 ; number:1 ; day:29 ; month:4 ; year:2021 ; pages:1-11 ; date:12.2021
BMC cardiovascular disorders ; 21, Heft 1 (29.4.2021), 1-11, 12.2021
- Creator
-
Oka, Satoshi
Kai, Takahiko
Hoshino, Katsuomi
Watanabe, Kazunori
Nakamura, Jun
Abe, Makoto
Watanabe, Akinori
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12872-021-02024-3
- URN
-
urn:nbn:de:101:1-2021061704303805791340
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oka, Satoshi
- Kai, Takahiko
- Hoshino, Katsuomi
- Watanabe, Kazunori
- Nakamura, Jun
- Abe, Makoto
- Watanabe, Akinori
- SpringerLink (Online service)
Other Objects (12)
Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung
Anti-inflammatory potential of Empagliflozin
Empagliflozin: a potential anticancer drug
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
The peripheral blood transcriptome in septic cardiomyopathy: an observational, pilot study
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung
Anti-inflammatory potential of Empagliflozin
Empagliflozin: a potential anticancer drug
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
The peripheral blood transcriptome in septic cardiomyopathy: an observational, pilot study
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Empagliflozin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-12
Empagliflozin/Metformin (Diabetes mellitus Typ 2) : Addendum zum Auftrag A16-13
Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) : Nutzenbewertung gemäß § 35a SGB V
Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Empagliflozin (Diabetes mellitus Typ 2 bei Kindern und Jugendlichen); Nutzenbewertung gemäß § 35a SGB V : Dossierbewertung
Anti-inflammatory potential of Empagliflozin
Empagliflozin: a potential anticancer drug
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
The peripheral blood transcriptome in septic cardiomyopathy: an observational, pilot study
Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy